PrEP pills combined with an ingestible sensor can identify patients who are adherent to the medication and those who are not, putting them at risk for HIV, according to a study.
“Our group had worked with the ingestible sensor system in tuberculosis treatment. As academic clinicians involved in clinical trials, we were impressed by how safe and accurate the technology was,” Sara H. Browne, MD, clinical professor of medicine at the University of California, San Diego School of Medicine, told Healio.
“The utility in TB treatment was obvious in terms of a more convenient option